Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes

American Journal of Health-System Pharmacy

Volumn 70, Issue 4, 2013, Pages 311-319

  Nisly, Sarah A ^a,b   Kolanczyk, Denise M ^c   Walton, Alison M ^a,d  

^a BUTLER UNIVERSITY   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d Ambulatory Care Eskenazi Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IPRAGLIFLOZIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2;

AREA UNDER THE CURVE; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ELECTROLYTE EXCRETION; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URINARY TRACT INFECTION; URINE VOLUME; VAGINA CANDIDIASIS; WEIGHT REDUCTION;

EID: 84874095570     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110514     Document Type: Review

References (36)

1. Centers for Disease Control and Prevention. National diabetes fact sheet, 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf (accessed 2012 Feb 9).
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35(suppl 1):S64-71.
3. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012; 35(suppl 1):S11-63.
4. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32:193-203.
5. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009; 15:540-59.
6. [Erratum, Endocr Pract. 2009; 15:768-70.]
7. Qaseem A, Humphrey LL, Sweet DE et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012; 156:218-31.
8. Riddle M. Combining sulfonylureas and other oral agents. Am J Med. 2000; 108(suppl 1):15-22.
9. Idris I, Donnelly R. Sodium-glucose cotransporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009; 11:79-88.
10. Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors. Drugs. 2010; 70:377-85.
11. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9:551-9.
12. Johnson & Johnson Pharmaceutical Research & Development reports phase 2b clinical trial results evaluating canagliflozin to treat type 2 diabetes. www.jnj.com/connect/news/all/Johnson-Johnson-R-D-Reports-Phase-2b- Clinical-Trial-Results-Evaluating-Canagliflozin (accessed 2010 Sep 14).
13. Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycaemic control in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012; 14:539-45.
14. Rosenstock J, Arbit D, Usiskin K et al. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin (abstract 77-OR). Diabetes. 2010; 59(suppl 1):A21.
15. Sha S, Devineni D, Gosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated (abstract 568-P). Diabetes. 2010; 59(suppl 1):A155.
16. Nicolle L, Usiskin K, Capuano G et al. No increase in bacteriuria or urinary tract infections in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin, a sodium glucose co-transporter (SGLT2) inhibitor (abstract 43-LB). Diabetes. 2011; 60(suppl 1A):LB12.
17. Nyirjesy P, Zhao Y, Usiskin K et al. Effects of canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, on vulvovaginal Candida colonization and symptomatic vulvovaginal candidiasis in patients with type 2 diabetes mellitus (T2DM) (abstract 32-LB). Diabetes. 2011; 60(suppl 1A):LB9.
18. Inagaki N, Kondo K, Iwasaki T et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM) (abstract 999-P). Diabetes. 2011: 60.
19. Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012; 14:83-90.
20. Ehrenkranz JR, Lewis NG, Kahn CR et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005; 21:31-8.
21. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008; 62:1279-84.
22. Patel AK, Fonseca V. Turning glucosuria into a therapy: efficacy and safety with SGLT2 inhibitors. Curr Diab Rep. 2010; 10:101-7.
23. Nair S, Wilding J P. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010; 95:34-42.
24. Wexler D, Vandebosch A, Usiskin K et al. Study of electrocardiogram intervals in healthy adults receiving single oral doses of canagliflozin (abstract 2177-PO). Diabetes. 2010; 59(suppl 1):A571.
25. Sarich T, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects (abstract 567-P). Diabetes. 2010; 59(suppl 1):A155.
26. Sha S, Devineni D, Gosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, induces dose-dependent urinary glucose excretion in healthy subjects (abstract 76-OR). Diabetes. 2010; 59(suppl 1):A21.
27. ClinicalTrials.gov, National Institutes of Health. http://clinicaltrials. gov/ct2/results?term=canagliflozin (accessed 2012 Feb 2).
28. Wright EM. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol. 2001; 280:F10-8.
29. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009; 53:875-83.
30. Bakris GL, Fonseca VA, Sharma K et al. Renal-sodium glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009; 75:1272-7.
31. Nomura S, Sakamaki S, Hongu M et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem. 2010; 53:6355-60.
32. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother. 2008; 42:817-26.
33. Brooks AM, Thacker SM. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother. 2009; 43:1286-93.
34. AstraZeneca. FDA advisory committee makes recommendation on investigational compound dapagliflozin. www.astrazeneca.com/Media/Press- releases/Article/20110720-dapagliflozin-advisory-committee-result (accessed 2011 Aug 26).
35. Lowry F. Dapagliflozin declined by the FDA. www.medscape.com/viewarticle/ 757175 (accessed 2012 Feb 2).
36. Johnson & Johnson. Janssen Research & Development submits new drug application to U.S. FDA for canagliflozin to treat patients with type 2 diabetes. www.investor.jnj.com/releaseDetail.cfm?releaseid=678690 (accessed 2012 Dec 21).